The role of homocysteine in bone remodeling

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 3, 2013, Pages 579-590

  Vacek, Thomas P ^a   Kalani, Anuradha ^a   Voor, Michael J ^a   Tyagi, Suresh C ^a   Tyagi, Neetu ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Bone remodeling; Collagen crosslinking; Matrix metalloproteinases; Oxidative stress

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; COLLAGEN; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; HYDROXYPROLINE; MATRIX METALLOPROTEINASE; REACTIVE OXYGEN METABOLITE;

AMINO ACID BLOOD LEVEL; BIOMECHANICS; BONE BLOOD FLOW; BONE DENSITY; BONE MATRIX; BONE METABOLISM; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; CONFERENCE PAPER; CROSS LINKING; CYANOCOBALAMIN DEFICIENCY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FOLIC ACID DEFICIENCY; HUMAN; HYPERHOMOCYSTEINEMIA; MITOCHONDRION; NONHUMAN; OSTEOBLAST; OSTEOCLAST ACTIVITY; OSTEOPOROSIS; OXIDATIVE STRESS; PRIORITY JOURNAL; VASCULARIZATION;

BONE REMODELING; COLLAGEN; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MATRIX METALLOPROTEINASES; MITOCHONDRIA; OSTEOPOROSIS; OXIDATIVE STRESS;

EID: 84882436145     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0605     Document Type: Conference Paper

References (93)

1. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke - a meta-analysis. J Am Med Assoc 2002;288:2015-22.
2. Sen U, Basu P, Abe OA, Givvimani S, Tyagi N, Metreveli N, et al. Hydrogen sulfide ameliorates hyperhomocysteinemia-associated chronic renal failure. Am J Physiol Renal Physiol 2009;297:410-9.
3. Lominadze D, Roberts AM, Tyagi N, Moshal KS, Tyagi SC. Homocysteine causes cerebrovascular leakage in mice. Am J Physiol Heart Cir Physiol 2006;290:1206-13.
4. Lips P. Epidemiology and predictors of fractures associated with osteoporosis. Am J Med 1997;103:3S-8S.
5. Riggs BL, Melton LJ 3rd. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995;17:505-11.
6. Tyagi N, Kandel M, Munjal C, Qipshidze N, Vacek JC, Pushpakumar SB, et al. Homocysteine mediated decrease in bone blood flow and remodeling: role of folic acid. J Orthop Res 2011;29:1511-6.
7. Herrmann M, Widmann T, Herrmann W. Homocysteine - a newly recognised risk factor for osteoporosis. Clin Chem Lab Med 2005;43:1111-7.
8. Van Wijngaarden JP, Dhonukshe-Rutten RA, Van Schoor NM, Van Der Velde N, Swart KM, Enneman AW, et al. Rationale and design of the B-PROOF study, a randomized controlled trial on the effect of supplemental intake of vitamin B12 and folic acid on fracture incidence. BMC Geriatr 2011;11:80.
9. Ozdem S, Samanci S, Tasatargil A, Yildiz A, Sadan G, Donmez L, et al. Experimental hyperhomocysteinemia disturbs bone metabolism in rats. Scand J Clin Lab Invest 2007;67:748-56.
10. Derkx P, Nigg AL, Bosman FT, Birkenhager-Frenkel DH, Houtsmuller AB, Pols HA. Immunolocalization and quantification of noncollagenous bone matrix proteins in methylmethacrylate-embedded adult human bone in combination with histomorphometry. Bone 1998;22:367-73.
11. Herrmann M, Kraenzlin M, Pape G, Sand-Hill M, Herrmann W. Relation between homocysteine and biochemical bone turnover markers and bone mineral density in peri-and postmenopausal women. Clin Chem Lab Med 2005;43:1118-23.
12. Blouin S, Thaler HW, Korninger C, Schmid R, Hofstaetter JG, Zoehrer R, et al. Bone matrix quality and plasma homocysteine levels. Bone 2009;44:959-64.
13. Wittenburg G, Volkel C, Mai R, Lauer G. Immunohistochemical comparison of differentiation markers on paraffin and plastic embedded human bone samples. J Physiol Pharmacol 2009;60:43-9.
14. Yang R, Davies CM, Archer CW, Richards RG. Immunohistochemistry of matrix markers in Technovit 9100 new-embedded undecalcified bone sections. Eur Cell Mater 2003;6:57-61.
15. Kramer I, Halleux C, Keller H, Pegurri M, Gooi JH, Weber PB, et al. Osteocyte Wnt/p-catenin signaling is required for normal bone homeostasis. Mol Cell Biol 2010;30:3071-5.
16. Herrmann M, Umanskaya N, Wildemann B, Colaianni G, Widmann T, Zallone A, et al. Stimulation of osteoblast activity by homocysteine. J Cell Mol Med 2008;12:1205-10.
17. Herrmann M, Tami A, Wildemann B, Wolny M, Wagner A, Schorr H, et al. Hyperhomocysteinemia induces a tissue specific accumulation of homocysteine in bone by collagen binding and adversely affects bone. Bone 2009;44:467-75.
18. Liu G, Nellaiappan K, Kagan HM. Irreversible inhibition of lysyl oxidase by homocysteine thiolactone and its selenium and oxygen analogues. Implications for homocystinuria. J Biol Chem 1997;272:32370-7.
19. Thaler R, Agsten M, Spitzer S, Paschalis EP, Karlic H, Klaushofer K, et al. Homocysteine suppresses the expression of the collagen cross-linker lysyl oxidase involving IL-6, Fli1, and epigenetic DNA methylation. J Biol Chem 2011;286:5578-88.
20. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000;102:33-42.
21. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000;6:513-9.
22. Li LY, Luo X, Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 2001;412:95-9.
23. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996;86:147-57.
24. Spiess C, Beil A, Ehrmann M. A temperature-dependent switch from chaperone to protease in a widely conserved heat shock protein. Cell 1999;97:339-47.
25. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999;397:441-6.
26. Van Loo G, Schotte P, Van Gurp M, Demol H, Hoorelbeke B, Gevaert K, et al. Endonuclease G: a mitochondrial protein released in apoptosis and involved in caspase-independent DNA degradation. Cell Death Differ 2001;8:1136-42.
27. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000;102:43-53.
28. Fu X, Kassim SY, Parks WC, Heinecke JW. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 2001;276:41279-87.
29. Moshal KS, Singh M, Sen U, Rosenberger DS, Henderson B, Tyagi N, et al. Homocysteine-mediated activation and mitochondrial translocation of calpain regulates MMP-9 in MVEC. Am J Physiol Heart Circ Physiol 2006;291:2825-35.
30. Moshal KS, Metreveli N, Frank I, Tyagi SC. Mitochondrial MMP activation, dysfunction and arrhythmogenesis in hyperhomocysteinemia. Curr Vasc Pharmacol 2008;6:84-92.
31. Itzstein C, Cheynel H, Burt-Pichat B, Merle B, Espinosa L, Delmas PD, et al. Molecular identification of NMDA glutamate receptors expressed in bone cells. J Cell Biochem 2001;82:134-44.
32. Kawahara I, Koide M, Tadokoro O, Udagawa N, Nakamura H, Takahashi N, et al. The relationship between calcium accumulation in osteoclast mitochondrial granules and bone resorption. Bone 2009;45:980-6.
33. Fajardo M, Liu CJ, Ilalov K, Egol KA. Matrix metalloproteinases that associate with and cleave bone morphogenetic protein-2 in vitro are elevated in hypertrophic fracture nonunion tissue. J Orthop Trauma 2010;24:557-63.
34. Galliera E, Banfi G, Corsi MM. Human bone disorders: pathological role and diagnostic potential of matrix metalloproteinases. Int J Biochem Cell Biol 2010;42:1590-3.
35. Hill PA, Murphy G, Docherty AJ, Hembry RM, Millican TA, Reynolds JJ, et al. The effects of selective inhibitors of matrix metalloproteinases (MMPs) on bone resorption and the identification of MMPs and TIMP-1 in isolated osteoclasts. J Cell Sci 1994;107:3055-64.
36. Murphy G, Reynolds JJ. Progress towards understanding the resorption of connective tissues. Bioessays 1985;2:55-60.
37. Pasternak B, Aspenberg P. Metalloproteinases and their inhibitors - diagnostic and therapeutic opportunities in orthopedics. Acta Orthop 2009;80:693-703.
38. Nathalie O, Danielle B, Dominique S, Zena W. How proteases regulate bone morphogenesis. Ann N Y Acad Sci 2003;995:109-16.
39. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994;370:61-5.
40. Alexandrakis MG, Sfiridaki A, Miyakis S, Pappa C, Kandidaki E, Alegakis A, et al. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma. Clin Chim Acta 2007;379:31-5.
41. Tyagi N, Sedoris KC, Steed M, Ovechkin AV, Moshal KS, Tyagi SC. Mechanisms of homocysteine-induced oxidative stress. Am J Physiol Heart Circ Physiol 2005;289:2649-56.
42. Koh JM, Lee YS, Kim YS, Kim DJ, Kim HH, Park JY, et al. Homocysteine enhances bone resorption by stimulation of osteoclast formation and activity through increased intracellular ROS generation. J Bone Miner Res 2006;21:1003-11.
43. Stunes AK, Westbroek I, Gustafsson BI, Fossmark R, Waarsing JH, Eriksen EF, et al. The peroxisome proliferator-activated receptor (PPAR) a agonist fenofibrate maintains bone mass, while the PPARγ agonist pioglitazone exaggerates bone loss, in ovariectomized rats. BMC Endocr Disord 2011;11:11.
44. Zhang L, Jin M, Hu XS, Zhu JH. Homocysteine stimulates nuclear factor kB activity and interleukin-6 expression in rat vascular smooth muscle cells. Cell Biol Int 2006;30:592-7.
45. Brude IR, Finstad HS, Seljeflot I, Drevon CA, Solvoll K, Sandstad B, et al. Plasma homocysteine concentration related to diet, endothelial function and mononuclear cell gene expression among male hyperlipidaemic smokers. Eur J Clin Invest 1999;29:100-8.
46. Inoue I, Noji S, Awata T, Takahashi K, Nakajima T, Sonoda M, et al. Bezafibrate has an antioxidant effect: peroxisome proliferator-activated receptor a is associated with Cu2+, Zn2+ superoxide dismutase in the liver. Life Sci 1998;63:135-144.
47. Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor a activation modulates cellular redox status, represses nuclear factor kB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998;273:32833-41.
48. Yilmaz N, Eren E. Homocysteine oxidative stress and relation to bone mineral density in post-menopausal osteoporosis. Aging Clin Exp Res 2009;21:353-7.
49. Herrmann M, Widmann T, Colaianni G, Colucci S, Zallone A, Herrmann W. Increased osteoclast activity in the presence of increased homocysteine concentrations. Clin Chem 2005;51:2348-53.
50. Kim DJ, Koh JM, Lee O, Kim NJ, Lee YS, Kim YS, et al. Homocysteine enhances apoptosis in human bone marrow stromal cells. Bone 2006;39:582-90.
51. Huang C, Ogawa R. Mechanotransduction in bone repair and regeneration. FASEB J 2010;24:3625-32.
52. Mi LY, Basu M, Fritton SP, Cowin SC. Analysis of avian bone response to mechanical loading. Part two: development of a computational connected cellular network to study bone intercellular communication. Biomech Model Mechanobiol 2005;4:132-6.
53. McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE, et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004;351:2042-9.
54. Zhu K, Beilby J, Dick IM, Devine A, Soos M, Prince RL. The effects of homocysteine and MTHFR genotype on hip bone loss and fracture risk in elderly women. Osteoporos Int 2009;20:1183-91.
55. Perier MA, Gineyts E, Munoz F, Sornay-Rendu E, Delmas PD. Homocysteine and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int 2007;18:1329-36.
56. Claes L, Schmalenbach J, Herrmann M, Olku I, Garcia P, Histing T, et al. Hyperhomocysteinemia is associated with impaired fracture healing in mice. Calcif Tissue Int 2009;85:17-21.
57. Levin ER. Plasma membrane estrogen receptors. Trends Endocrinol Metab 2009;20:477-82.
58. Aaron W, Alexander A, Brugmann SA, Xu Y, Carre AL, Leucht P, et al. Estrogen/estrogen receptor a signaling in mouse posterofrontal cranial suture fusion. PLoS One 2009;4:e7120.
59. Bayhan I, Uygur D, Ugurlu N, Ozaksit G. Strontium ranelate decreases plasma homocysteine levels in postmenopausal osteoporotic women. Rheumatol Int 2009;29:263-6.
60. Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001;69:121-9.
61. Buehler J, Chappuis P, Saffar JL, Tsouderos Y, Vignery A. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone 2001;29:176-9.
62. Mijatovic V, Van Der Mooren MJ. Homocysteine in postmenopausal women and the importance of hormone replacement therapy. Clin Chem Lab Med 2001;39:764-7.
63. Holstein JH, Herrmann M, Splett C, Herrmann W, Garcia P, Histing T, et al. Hyperhomocysteinemia is not associated with reduced bone quality in humans with hip osteoarthritis. Clin Chem Lab Med 2010;48:821-7.
64. Mobasseri M, Aliasgharzadeh A, Ebrahimzadeh Z, Najafipoor F, Niafar M, Aghamohammadzadeh N, et al. Hyperhomocysteinemia and bone mineral density: a case-control study. Pak J Med Sci 2009;25:91-6.
65. Herrmann M, Wildemann B, Claes L, Klohs S, Ohnmacht M, Taban-Shomal O, et al. Experimental hyperhomocysteinemia reduces bone quality in rats. Clin Chem 2007;53:1455-61.
66. Fleming JT, Barati MT, Beck DJ, Dodds JC, Malkani AL, Parameswaran D, et al. Bone blood flow and vascular reactivity. Cells Tissues Organs 2001;169:279-84.
67. Ness J, Aronow WS. Comparison of prevalence of atherosclerotic vascular disease in postmenopausal women with osteoporosis or osteopenia versus without osteoporosis or osteopenia. Am J Cardiol 2006;97:1427-8.
68. McCarthy ID. Fluid shifts due to microgravity and their effects on bone: a review of current knowledge. Ann Biomed Eng 2005;33:95-103.
69. Wimalawansa SJ. Nitric oxide and bone. Ann NY Acad Sci 2010;1192:391-403.
70. Studer RK, Decker K, Melhem S, Georgescu H. Nitric oxide inhibition of IGF-1 stimulated proteoglycan synthesis: role of cGMP. J Orthop Res 2003;21:914-21.
71. Sunyer T, Rothe L, Kirsch D, Jiang X, Anderson F, Osdoby P, et al. Ca2+ or phorbol ester but not inflammatory stimuli elevate inducible nitric oxide synthase messenger ribonucleic acid and nitric oxide (NO) release in avian osteoclasts: autocrine NO mediates Ca2+-inhibited bone resorption. Endocrinology 1997;138:2148-62.
72. Tyagi N, Vacek TP, Fleming JT, Vacek JC, Tyagi SC. Hyperhomocysteinemia decreases bone blood flow. Vasc Health Risk Manag 2011;7:31-5.
73. Banfi G, Iorio EL, Corsi MM. Oxidative stress, free radicals and bone remodeling. Clin Chem Lab Med 2008;46:1550-5.
74. Sanchez-Rodrfguez MA, Ruiz-Ramos M, Correa-Munoz E, Mendoza-Nunez VM. Oxidative stress as a risk factor for osteoporosis in elderly Mexicans as characterized by antioxidant enzymes. BMC Musculoskel Disord 2007;19:124.
75. Fleming JT, Barati MT, Beck DJ, Dodds JC, Malkani AL, Parameswaran D, et al. Bone blood flow and vascular reactivity. Cells Tissues Organs 2001;169:279-84.
76. Lucock M. Folic acid: nutritional biochemistry, molecular biology, and role in disease processes. Mol Genet Metab 2000;71:121-8.
77. Das UN. Folic acid says NO to vascular diseases. Nutrition 2003;19:686-92.
78. Vaes BL, Lute C, Blom HJ, Bravenboer N, De Vries TJ, Everts V, et al. Vitamin B (12) deficiency stimulates osteoclastogenesis via increased homocysteine and methylmalonic acid. Calc Tissue Int 2009;84:413-22.
79. Krivosfkova Z, Krajcovicova-Kudlackova M, Spustova V, Steffkova K, Valachovicova M, Blazicek P, et al. The association between high plasma homocysteine levels and lower bone mineral density in Slovak women: the impact of vegetarian diet. Eur J Nutr 2010;49:147-53.
80. Herrmann M, Wildemann B, Wagner A, Wolny M, Schorr H, Taban-Shomal O, et al. Experimental folate and vitamin B12 deficiency does not alter bone quality in rats. J Bone Miner Res 2009;24:589-96.
81. Kriebitzsch C, Verlinden L, Eelen G, Van Schoor NM, Swart K, Lips P, et al. 1, 25-Dihydroxyvitamin D3 influences cellular homocysteine levels in murine preosteoblastic MC3T3-E1 cells by direct regulation of cystathionine p-synthase. J Bone Miner Res 2011;26:2991-3000.
82. Dhonukshe-Rutten RA, Pluijm SM, De Groot LC, Lips P, Smit JH, Van Staveren WA, et al. Homocysteine and vitamin B12 status relate to bone turnover markers, broadband ultrasound attenuation, and fractures in healthy elderly people. J Bone Miner Res 2005;20:921-9.
83. Morris MS, Jacques PF, Selhub J. Relation between homocysteine and B-vitamin status indicators and bone mineral density in older Americans. Bone 2005;37:234-42.
84. Golbahar J, Hamidi A, Aminzadeh MA, Omrani GR. Association of plasma folate, plasma total homocysteine, but not methylenetetrahydrofolate reductase C667T polymorphism, with bone mineral density in postmenopausal Iranian women: a crosssectional study. Bone 2004;35:760-5.
85. Yazdanpanah N, Zillikens MC, Rivadeneira F, De Jong R, Lindemans J, Uitterlinden AG, et al. Effect of dietary B vitamins on BMD and risk of fracture in elderly men and women: the Rotterdam study. Bone 2007;41:987-94.
86. Herrmann M, Umanskaya N, Traber L, Schmidt-Gayk H, Menke W, Lanzer G, et al. The effect of B-vitamins on biochemical bone turnover markers and bone mineral density in osteoporotic patients: a 1-year double blind placebo controlled trial. Clin Chem Lab Med 2007;45:1785-92.
87. Kim GS, Kim CH, Park JY, Lee KU, Park CS. Effects of vitamin B12 on cell proliferation and cellular alkaline phosphatase activity in human bone marrow stromal osteoprogenitor cells and UMR106 osteoblastic cells. Metabolism 1996;45:1443-6.
88. Melhus H, Michaelsson K, Holmberg L, Wolk A, Ljunghall S. Smoking, antioxidant vitamins, and the risk of hip fracture. J Bone Miner Res 1999;14:129-35.
89. Lumbers M, New SA, Gibson S, Murphy MC. Nutritional status in elderly female hip fracture patients: comparison with an age-matched home living group attending day centres. Br J Nutr 2001;85:733-40.
90. Carmel R, Lau KH, Baylink DJ, Saxena S, Singer FR. Cobalamin and osteoblast-specific proteins. N Engl J Med 1988;319:70-5.
91. Roblin X, Phelip JM, Genevois M, Ducros V, Bonaz B. Hyperhomocysteinaemia is associated with osteoporosis in patients with Crohn's disease. Aliment Pharmacol Ther 2007;25:797-804.
92. McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE, et al. Homocysteine as a predictive factor for hip fracture in older persons. N Eng J Med 2004;350:2042-9.
93. Leboff MS, Narweker R, La Croix A, Wu L, Jackson R, Lee J, et al. Homocysteine levels and risk of hip fracture in postmenopausal women. J Clin Endocrinol Metab 2009;94:1207-13.